Crossmark

Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL

Crossref DOI link: https://doi.org/10.1186/s12967-019-1951-y

Published Online: 2019-06-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Perfecto-Avalos, Yocanxóchitl

Garcia-Gonzalez, Alejandro

Hernandez-Reynoso, Ana

Sánchez-Ante, Gildardo

Ortiz-Hidalgo, Carlos

Scott, Sean-Patrick

Fuentes-Aguilar, Rita Q.

Diaz-Dominguez, Ricardo

León-Martínez, Grettel

Velasco-Vales, Verónica

Cárdenas-Escudero, Mara A.

Hernández-Hernández, José A.

Santos, Arturo

Borbolla-Escoboza, José R.

Villela, Luis
Funding

Funding for this research was provided by:

CONACyT (SSA/IMSS/ISSSTE-CONACYT-2008-1-86825, SSA/IMSS/ISSSTE-CONACYT-2012-C01-180096)
License Information

Text and Data Mining valid from 2019-06-11

Version of Record valid from 2019-06-11
More Information

Article History

Received: 28 April 2019

Accepted: 5 June 2019

First Online: 11 June 2019

Ethics approval and consent to participate

: Mexican-mestizo data and sample collection was approved by the Institutional Review Board of Escuela de Medicina y Ciencias de la Salud from Tecnologico de Monterrey (Registration Number: C-HEMCAN-ITESM-02/08).

: Not applicable.

: LV has participated in advisory boards for Celgene, Amgen, and Takeda International; and has participated in speakers bureaus for Takeda International, Takeda Mexico, Celgene Mexico, Abbvie Mexico, and Roche Mexico.JRBE is employed by Novartis.

Document is current

Any future updates will be listed below